Amgen And UCB Announce FDA Advisory Committee Meeting To Review EVENITY™ (romosozumab) For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture Read more about Amgen And UCB Announce FDA Advisory Committee Meeting To Review EVENITY™ (romosozumab) For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture
Amgen To Webcast Investor Call At ASH 2018 Read more about Amgen To Webcast Investor Call At ASH 2018
Amgen To Present At the Piper Jaffray And Evercore ISI Healthcare Conferences Read more about Amgen To Present At the Piper Jaffray And Evercore ISI Healthcare Conferences
Amgen Receives CHMP Positive Opinion To Expand Use Of BLINCYTO® (Blinatumomab) In Patients With Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia Read more about Amgen Receives CHMP Positive Opinion To Expand Use Of BLINCYTO® (Blinatumomab) In Patients With Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia
Amgen Presents Results Highlighting The Long-Term Safety And Efficacy Of Repatha® (Evolocumab) In The Longest Duration Study Of A PCSK9 Inhibitor To Date At AHA Scientific Sessions 2018 Read more about Amgen Presents Results Highlighting The Long-Term Safety And Efficacy Of Repatha® (Evolocumab) In The Longest Duration Study Of A PCSK9 Inhibitor To Date At AHA Scientific Sessions 2018
Amgen Foundation Pledges $500,000 In Relief To Victims Of Ventura And Los Angeles County Wildfires Read more about Amgen Foundation Pledges $500,000 In Relief To Victims Of Ventura And Los Angeles County Wildfires
Amgen Announces Presentation Of Research Reinforcing The Long-Term Safety And Efficacy Of Repatha® (Evolocumab) In High-Risk Patients At AHA Scientific Sessions 2018 Read more about Amgen Announces Presentation Of Research Reinforcing The Long-Term Safety And Efficacy Of Repatha® (Evolocumab) In High-Risk Patients At AHA Scientific Sessions 2018
Amgen And Provention Bio Announce Co-Development Collaboration In Celiac Disease Read more about Amgen And Provention Bio Announce Co-Development Collaboration In Celiac Disease
Amgen To Present New Data Showcasing Extensive Portfolio And Exciting Early Oncology Pipeline At ASH 2018 Read more about Amgen To Present New Data Showcasing Extensive Portfolio And Exciting Early Oncology Pipeline At ASH 2018
Amgen Foundation Deepens Commitment To Aspiring Scientists Worldwide By Expanding Amgen Scholars Program Read more about Amgen Foundation Deepens Commitment To Aspiring Scientists Worldwide By Expanding Amgen Scholars Program
